63
Participants
Start Date
August 18, 2022
Primary Completion Date
July 12, 2023
Study Completion Date
July 27, 2023
TNX-102 SL
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Tonix Clinical Site, New York
Tonix Clinical Site, Williamsville
Tonix Clinical Site, Shelby
Tonix Clinical Site, Alpharetta
Tonix Clinical Site, Atlanta
Tonix Clinical Site, Orlando
Tonix Clinical Site, Aventura
Tonix Clinical Site, St. Petersburg
Tonix Clinical Site, Fort Myers
Accel Research-Birmingham Clinical Research Unit, Birmingham
Tonix Clinical Site, Gulfport
Tonix Clinical Site, Columbus
Tonix Clinical Site, Dayton
Tonix Clinical Site, Des Moines
Tonix Clinical Site, Iowa City
Tonix Clinical Site, Chicago
Tonix Clinical Site, Prairie Village
Tonix Clinical Site, New Orleans
Tonix Clinical Site, Prairieville
Tonix Clinical Site, Tulsa
Tonix Clinical Site, McKinney
Tonix Clinical Site, Austin
Tonix Clinical Site, Centennial
Tonix Clinical Site, Albuquerque
Tonix Clinical Site, Oceanside
Tonix Clinical Site, Santa Ana
Tonix Clinical Site, Boston
Tonix Clinical Site, Boston
Tonix Clinical Site, Methuen
Tonix Pharmaceuticals, Inc.
INDUSTRY